GO
Loading...

Drugs

More

  • Will ghoulish investments pay off? Monday, 16 Jun 2014 | 6:57 PM ET
    Elderly women wait for lunch to be served at a day care facility on Gogo Island in Matsuyama, Ehime Prefecture, Japan

    As the global population ages, some see investment opportunities in somewhat ghoulish bets the rates of cancer and other illnesses will rise.

  • Mexico's most feared drug cartel     Thursday, 12 Jun 2014 | 1:32 PM ET

    CNBC's Andrea Day looks into the FBI's investigation of the Los Zetas drug cartel, which used horse racing to launder money.

  • Orexigen shares plunge on FDA diet-drug delay Wednesday, 11 Jun 2014 | 7:33 AM ET

    Orexigen Therapeutics said the FDA delayed a decision on its obesity drug by three months, sending the company's shares down about 19 percent.

  • Merck proud to be a US-based company: CEO Wednesday, 4 Jun 2014 | 8:52 AM ET
    Ken Frazier, president and CEO of Merck.

    But Merck chief Kenneth Frazier also said the government needs to modify its high corporate tax code to level the playing field for American companies.

  • June 3- The city of Chicago has filed a lawsuit against five large narcotics makers alleging they contributed to the country's prescription drug epidemic by deceptively promoting their painkillers.

  • Chicago sues drugmakers, alleging painkiller risk Tuesday, 3 Jun 2014 | 10:37 AM ET

    Chicago filed a lawsuit against five pharmaceutical companies, accusing them of concealing the risks associated with certain painkillers.

  • Hate shots? New allergy options are on the way Monday, 2 Jun 2014 | 7:03 AM ET

    Patients can try new once-a-day tablets that dissolve quickly under the tongue and raise tolerance to grass or ragweed pollen, much like the shots.

  • What new GSK cancer deal shows about pharma market Monday, 2 Jun 2014 | 3:33 AM ET

    The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.

  • Immunotherapies hit ASCO     Thursday, 29 May 2014 | 3:35 PM ET

    This year's biggest cancer conference begins tomorrow. CNBC's Meg Tirrell reports why immunotherapy drugs will be a key theme with drug makers at ASCO.

  • GSK invites private equity bid for drugs: Sources Thursday, 29 May 2014 | 12:34 PM ET
    A GlaxoSmithKline Plc logo sits on a sign outside the company's headquarters in London, U.K.

    GSK has invited private equity firms to consider making offers for a range of its older drugs, three people with direct knowledge of the matter said.

  • NEW YORK, May 29- Three Connecticut doctors billed Medicare for nearly 24,000 drug tests in 2012- on just 145 patients. Despite the extraordinary number, Medicare administrators paid the doctors a total of $1.4 million, according to a Reuters analysis of government payments to health providers.

  • Ataluren drives PTC Therapeutics     Friday, 23 May 2014 | 10:25 AM ET

    CNBC's Meg Tirrell reports shares of PTC Therapeutics are surging on a recommendation of the drug "Ataluren" designed to treat Duchenne muscular dystrophy which could be a billion dollar drug.

  • LONDON, May 20- Smokers trying to quit are 60 percent more likely to report success if they switch to e-cigarettes than if they use nicotine products like patches or gum, or just willpower, scientists said on Wednesday.

  • Pfizer: A deal to dodge the tax man in America Tuesday, 13 May 2014 | 2:28 AM ET

    Pfizer's pursuit of AstraZeneca raises a huge public policy red flag, writes Andrew Ross Sorkin in the New York Times.

  • Colombian Finance Minister Mauricio C├írdenas Santamaria says resolving the country's drugs issue will help the country post stronger growth.

  • Teva's abuse-resistant painkiller succeeds in study Wednesday, 30 Apr 2014 | 8:33 AM ET

    April 30- Israel's Teva Pharmaceutical Industries Ltd said its experimental abuse-resistant pain drug significantly reduced patients' chronic low back pain in a late-stage trial. The drug is a twice-daily formulation of hydrocodone, which belongs to a powerful class of painkillers known as opioids that are also frequently abused.

  • Biogen barreling down on Alzheimer's     Wednesday, 23 Apr 2014 | 3:33 PM ET

    CNBC's Meg Tirrell speaks with George Scangos, Biogen Idec CEO, about the drug maker's fight against MS and Alzheimer's. Scangos also comments on Valeant's bid for Alllergan.

  • Investor pressure pushing drugmaker M&A deals Wednesday, 23 Apr 2014 | 6:11 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.

  • On a high: Hemp to boost US economy?     Wednesday, 16 Apr 2014 | 11:40 AM ET

    The hemp industry could become one of the U.S.'s biggest now its industrial use had been legalized, says Doug Fine, author of "Hemp Bound".

  • District Court judge on Tuesday stopped Massachusetts from implementing a ban on the sale of Zogenix Inc's prescription painkiller Zohydro, saying federal law superseded the state's action.